SenzaGen granted its first patent for GARD™potency
SenzaGen's patent application that protects the biomarker signature to measure how strongly allergenic a substance is, has now been granted in Europe. The patent is SenzaGen's first patent in the area of potency classification. The patent's validity extends to 2036.
The technology of SenzaGen's patent is implemented in the company's testing application, which for the first time makes it possible to measure the allergenicity of chemical substances, so-called potency classification, without animal research.
“Getting this patent on the European market is commercially interesting, as there is a ban within the EU on the sale of animal-tested cosmetic products. Furthermore, to quantify how strong the allergenic effect is according to CLP / GHS is a requirement in the EU chemical regulation REACH. As the only company in the world, SenzaGen can now offer an animal-free test method for this”, says Anki Malmborg Hager, CEO of SenzaGen.
SenzaGen’s IP strategy is to protect the company’s technology in all geographically important markets. Already granted in Europe, China and Hong Kong, patent applications for GARD™skin are currently being processed by the patent authorities in countries where animal testing is prohibited or where a ban is expected to be introduced, including the United States, Canada and India. In addition, the patent portfolio includes several ongoing patent applications for GARD™potency and other GARD™ products.
SenzaGen’s GARD™ product portfolio consists of a set of allergy tests with industry leading performance and accuracy. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence, and replace animal experiments for the cosmetics, chemical and pharmaceutical industries for their tests on whether chemical substances in products can be allergenic.
For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com | Mobil: 0768 284822
Tina Dackemark Lawesson, Director Investor Relations & Corporate Communications
Email: tina.lawesson@senzagen.com | Mobil: 0708 202944
About GARD™
GARD™ consists of a group of tests for analyzing chemicals’ ability to start an allergic reaction in humans. By analyzing hundreds of markers, GARD™ generates large amounts of data and delivers results with over 90 percent accuracy. This can be compared to today’s standard method – tests on mice – which only achieves 70-75 percent precision. SenzaGen’s test can also quantify the allergenic potential of a chemical substance.
About SenzaGen AB (publ)
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact within our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. The tests are sold via license laboratories (CRO) and distributors, and via the headquarters in Lund and the sales office in the US. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the USA. For more information visit www.senzagen.com.
SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399 info@fnca.se, is the company’s Certified Adviser.
